Breaking News
Get 50% Off 0
📈 Q4 Earnings Alert! Plan ahead with key data on upcoming stock reports - all in 1 place
See Calendar
Close

Moderna Inc (MRNA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Moderna's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
42.23 +2.12    +5.29%
13/02 - Closed. Currency in USD
After Hours
42.34
+0.12
+0.28%
19:59:39 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 16,336,584
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 41.20 - 44.80
Moderna 42.23 +2.12 +5.29%

Moderna Option Chain

 
View the MRNA options chain and compare options of Moderna stock. Analyze the various options available, including call options (the right to buy) and put options (the right to sell), along with their strike prices and expiration dates. Evaluate the prices and premiums associated with these options to make informed decisions about your trading strategies. Assess the Open Positions chart to find information about the distribution of open options contracts for MRNA stock at various strike prices and expiration dates. Gain insights into the options market sentiment and the potential trading activity surrounding the Moderna stock.
Expiration Date:
Show:
Strike Price:
Feb 13, 2026 08:14PM GMT

Calls

Puts

Last Chg. Bid Ask Vol Strike Last Chg. Bid Ask Vol
34.44 0% 27.1 30.7 0 14.00 0.14 0% 0 2.13 0
24.83 0% 26.1 29.6 0 15.00 0.05 0% 0 2.13 0
0 0% 25.1 28.4 0 16.00 0.01 0% 0 0.04 0
42.73
Price @ Feb 13, 2026 08:14PM GMT
1.51 15.27% 1.42 1.63 1,261 43.00 1.56 -61.95% 1.45 1.65 502
1.27 20.95% 1.21 1.36 2,347 43.50 1.89 0% 1.63 1.92 482
1.15 23.66% 1.04 1.15 6,841 44.00 2.15 -55.85% 1.92 2.21 109

Open Positions

 Calls
 Puts
© 2016 Market data provided and hosted by Barchart Market Data Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MRNA Comments

Write your thoughts about Moderna Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Joe Jordan
Joe Jordan Feb 14, 2026 6:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Moderna's stock is poised for potential upside in 2026, aligned with expected readouts from key studies like the Phase 3 intismeran autogene (mRNA-4157) trial in melanoma, Phase 2b five-year data, and norovirus Phase 3 results. The company forecasts up to 10% revenue growth, fueled by international sales, vaccine approvals (e.g., flu mRNA-1010, combo mRNA-1083), and oncology pipeline progress, which could drive positive valuation impacts if successful. While forecasts vary—some predict modest gains around $30-45, others see surges to $300+ on strong data—clinical successes remain pivotal for lifting MRNA's value.
Suman Bista
Suman Bista Feb 13, 2026 8:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Moving towards $60
Neil Young
Neil Young Jan 16, 2026 7:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$41.83 (+6%)
Nero Eino
Nero Eino Jan 14, 2026 7:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Investing in Moderna is just throwing money down the drain. $25 stock.
david lee
david lee Jan 13, 2026 8:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
selling
Yann Kash
Yann Kash Jan 13, 2026 1:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
incredible movement, buy or sell?
Suman Bista
Suman Bista Jan 13, 2026 12:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Heading to $60
kiven Geldon
kiven Geldon Jan 06, 2026 7:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nasty genetic goop turning humans into lab rats. No one wants to be a GMO
Neil Young
Neil Young Dec 23, 2025 4:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$32.28 (-7%)
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email